Naoya Fujita

14PUBLICATIONS
32CO-AUTHORS
Molecular targetsPredictive and prognostic markersEpidemiological modellingCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jan 06, 2025
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.

Kohei Maruyama, Yuki Shimizu, Yumi Nomura

|Dec 11, 2024
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.

Satoshi Takagi, Mikako Nakajima, Sumie Koike

|Feb 24, 2024
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.

Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara

|Aug 11, 2022
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.

Takuya Sakashita, Noriko Yanagitani, Sumie Koike

|Apr 05, 2022
Targeting Podoplanin for the Treatment of Osteosarcoma.

Ai Takemoto, Satoshi Takagi, Takao Ukaji

|Mar 18, 2022
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.

Yuki Shimizu, Koutaroh Okada, Jun Adachi

Pageof 3

Frequent Collaborators

12 joint publications

Ryohei Katayama

3 joint publications

Satoshi Takagi

3 joint publications

Yasushi Okuno

3 joint publications

Mitsugu Araki